Expertise with a Fresh Perspective

Expertise with a Fresh Perspective

Epikast combines decades of industry knowledge with AI tools and modern thinking to deliver results that are clear, agile, and built around you.

Our Mission

To simplify engagement and deliver outcomes that matter, enabling you to accelerate impact with clarity and confidence.

Our Mission

Our Difference

Flexible

Flexible

Solutions built around your challenges.

Approachable

Approachable

A partner that feels like part of your team.

Simple

Simple

Clear, streamlined, and easy to work with.

Expert yet fresh

Expert yet fresh

Seasoned knowledge with modern thinking.

Why It Matters

Because behind every engagement is a mission to improve lives. We exist to make that mission clearer, faster, and more achievable.

Why It Matters

Our Leadership

Stelios Papadopoulos, PhD

Chairman of the board

Stelios Papadopoulos, PhD

Chairman of the board

Stelios brings more than four decades of experience in the biopharmaceutical industry in various roles: as a company founder, executive, investment banker, and leader in the global healthcare sector.

In addition to his role as our co-founder and Chairman, Stelios is Chairman of the Board of Directors of Exelixis, Inc., and a member of the board of Graviton Biosciences Corp and Ovid Therapeutics, Inc. He is a co-founder of Exelixis, as well as former Chairman of Regulus Therapeutics (acquired by Novartis in 2025), and co-founder and former Chairman of Anadys Pharmaceuticals (acquired by Hoffman–La Roche in 2011) and Cellzome (acquired by GlaxoSmithKline in 2012). Until recently he was the Chairman of Biogen, having joined that board in 2008. In the not-for-profit sector, Stelios is co-founder and Chairman of Fondation Santé, a foundation providing research support and mentorship to biomedical scientists in Greece and Cyprus.

Stelios spent six years (2000-06) at Cowen & Co., LLC, most recently as Vice Chairman, where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in 1987 from Drexel Burnham Lambert where he was an analyst in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was the biotechnology analyst of Donaldson, Lufkin & Jenrette. Stelios has received multiple honors and awards for his work in the biopharma industry as a company founder, adviser, and financier.

Before coming to Wall Street, Stelios was in the faculty of the Department of Cell Biology at New York University School of Medicine. Stelios holds an MS in physics, a PhD in biophysics, and an MBA in finance, all from New York University.

Vangelis Vergetis, PhD

CEO and board member

Vangelis Vergetis, PhD

CEO and board member

Vangelis has been working in the intersection of healthcare, technology, and data science for 20 years.

He started his career as a consultant at McKinsey and at Hakluyt, where he spent twelve years advising biopharmaceutical executives on several topics - particularly in launching drugs across disease areas, and in designing and implementing their commercial models and infrastructure.

Immediately prior to Epikast, Vangelis was the co-founder and CEO of Intelligencia, a software company that utilizes AI to assess and reduce the risk of clinical trials. He currently serves as a board advisor to the company.

Vangelis is a member of the External Review Committee for the Technology Development Fund at Memorial Sloan Kettering Cancer Center, and he previously served as a founding board member and member of the executive committee at the Alliance for AI in Healthcare (AAIH), and as member of the dean's advisory board for Cornell's Bowers College of Computing & Information Science (CIS).

He holds a PhD in Electrical Engineering from the University of Pennsylvania, and a BS in Computer Science from Cornell University.

Konstantinos Arsenos

VP, Operations

Konstantinos Arsenos

VP, Operations

Konstantinos serves as Epikast’s Operations Manager, based at our office in Athens. He leads our broader team that delivers exceptional experiences related to supporting and engaging with patients, physicians, and other healthcare providers. He focuses on innovation and the use of the latest technologies, driving continuous improvement and agility, and enhancing efficiency in the company’s growing operations.

Before joining Epikast, Konstantinos spent ~20 years in the pharma sector, initially as a sales representative and eventually leading teams at Alcon and Novartis. His extensive experience across operations and his expert grasp of digital technologies have enabled him to successfully lead teams with a holistic approach to serving clients. He is committed to ensuring that Epikast's operations are always at the forefront of innovation in the healthcare industry.

He holds an MBA and a BS in Business, both from the University of Glamorgan in Wales.

Tim Ayers, JD, MPH

Head of Compliance

Tim Ayers, JD, MPH

Head of Compliance

Tim has over 25 years of experience in life sciences compliance across different organizations in the US and Europe. He leads our Compliance function and serves as both General Counsel and Compliance Officer for various other life science companies, ranging from pre-commercial to commercial and global life science entities.

Previously, he was the Chief Compliance Officer for Horizon Pharma. He has held various legal and compliance roles at small biotech companies, starting his in-house work at Pfizer in 2004. Prior to joining the in-house ranks, Tim was an attorney in the healthcare group at Winston & Strawn, LLP, at their Washington DC, office.

He obtained both his JD and BA degrees from Georgetown University, and he also holds an MPH from Columbia University.

Christos Christodoulou, PhD

Head of AI

Christos Christodoulou, PhD

Head of AI

Christos has 10 years of experience in data science, data engineering and product management, having led teams across multiple verticals and industries, with a focus on data, machine learning, and AI.

Prior to Epikast he was a Senior Product Manager at Orfium (AI company in media/music), a Data, Product, and Engineering Lead at Klarna (a $20B+ EU-based fintech company), the Head of Data Insights at T-Systems (part of Deutsche Telekom), and an AI Program Manager at The Cyprus Institute (research and education non-profit). He started his career as a postdoctoral researcher in physics at Helmholtz-Zentrum Berlin (HZB).

Christos holds a PhD in physics from Humboldt University Berlin and a BA/MS in Physics / Natural Sciences from Cambridge University in the UK.

Elli Exarchopoulou, MBA

VP, Customer Success

Elli Exarchopoulou, MBA

VP, Customer Success

Elli has been working in biopharma for over a decade. She started as a management consultant at Deloitte, and subsequently transitioned to operating roles at Biogen and Lilly, across the US and Europe.

In her latest role she led Biogen's Rare Disease portfolio in the UK and Ireland, and prior to that she spent 6 years with Lilly across a variety of commercial, marketing, and market access roles in the US, the UK, Ireland, and the Nordic markets. She has worked on new product launches, brand strategy, go-to-market strategies, and multi-channel campaigns across oncology, precision medicine, immunology, and rare diseases. Earlier in her career she worked at the European Commission, OECD, and the United Nations.

Elli holds an MBA from Harvard Business School, an MPhil in International Relations from the University of Cambridge, and a BA in Political Science and History from the University of Warwick and UC Berkeley.

Tara Goodman, MPH

VP, Commercial

Tara Goodman, MPH

VP, Commercial

Tara is a VP of Commercial, working with our customers in identifying how Epikast can best support them as they meaningfully engage patients, physicians, and other HCPs. She has 20+ years of experience in life sciences, with expertise in various strategic roles across commercial services, clinical services, software, and data.

Prior to Epikast, Tara was a SVP of Life Sciences at Komodo Health, a VP of Life Sciences at PointClickCare, and has held various Business Development roles across CROs for 15+ years: Parexel, INC Research (now part of Syneos), and Charles River Laboratories.

Tara holds an MPH in Health Management and Policy and a BA in Biology and Psychology, both from Emory University.

Daphne Karydas

Board member

Daphne Karydas

Board member

Daphne has over 25 years of experience in financial and operations leadership roles focused in the biopharmaceutical industry, where she has brought an interdisciplinary approach to implementing growth strategies for biopharmaceutical and asset management companies.

She is currently the President and CFO of Flare Therapeutics, which she joined in October 2021. Prior to Flare she was the CFO of Syndax Pharmaceuticals, and also served as SVP of Strategy and Corporate Financial Planning & Analysis at Allergan plc, where she oversaw the company’s long-term financial and business strategy until its acquisition by Abbvie in May 2020. She joined Allergan in April 2017 as the SVP of Global Investor Relations and Strategy, leading engagement with the investment community and business strategy development.

In addition to her role at Flare, Daphne is a board member at Mineralys Therapeutics and Compass Pathways, and has previously served on the borads of Elicio Therapeutics and LogicBio Therapeutics (acquired by Alexion / AstraZeneca).

Prior to her senior operating roles in the industry, Daphne served as Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management. Previously, she was a Portfolio Manager and Senior Healthcare Analyst at The Boston Company Asset Management, a BNY Mellon company. Earlier in her career she was a VP at Goldman Sachs Asset Management focused on healthcare, as well as a member of Goldman Sachs’ healthcare investment banking team. Before joining Goldman Sachs she was a Project Chemical Engineer at Merck, where she focused on process development for novel vaccines.

Daphne received a BA and MS in chemical engineering from MIT and an MBA from Harvard Business School.

Lynn Kasper

VP, Commercial

Lynn Kasper

VP, Commercial

Lynn is a VP of Commercial, working with our customers in identifying how Epikast can best support them as they meaningfully engage patients, physicians, and other HCPs. She has over 25 years of experience in life sciences, with expertise in various strategic roles across commercial services, clinical services, software, and data.

Prior to Epikast, Lynn spent ~20 years in various business development roles of increasing responsibility at IQVIA (and IMS Health, prior to its acquisition). She has also served as a VP of Strategy and Business Development at Amplity Health, a VP of Strategic Development and Partnerships at Huma.AI, a VP of Global Strategy at H1.

Lynn holds a BS in Economics & Finance from Villanova University.

Mike Krzan

Advisor

Mike Krzan

Advisor

Mike brings a lifetime of experience in building and running high-performing patient services organizations, having spent more than 20 years in the space. He led Biogen’s patient services center in North Carolina for more than a decade, and prior to that was a SVP for member services and pharmacy operations at Medco.

While at Biogen, Mike was a member of the US Senior Leadership Team, developed and set the direction for the patient services organization to support $8B of revenue, launched seven products (including a blockbuster drug and an orphan drug), and collaborated with field sales leaders to identify trends, define tactics for improved performance, and ensure national team alignment.

He holds a BS in Pharmacy from Duquesne University.

Francois Lubbe

Head of Technology

Francois Lubbe

Head of Technology

Francois has been working in technology and software engineering for more than two decades, having led software engineering teams across multiple industries.

Immediately prior to Epikast he was the Product Owner at ACI worldwide, a company that develops payment software used by most of the world’s largest banks and financial intermediaries. Prior to that he spent 8 years as a technical manager at Clickatell, a company that develops AI-assisted chat/messaging channels to engage customers across different industries, and in various other software / systems administration roles at Upfront Systems (software development), Adept ICT (internet service provider), and Ackermans (retail).

Francois holds a Diploma in IT from Cape Peninsula University of Technology, and a Bachelor of Commerce from Stellenbosch University, both in South Africa.

Oleg Nodelman

Board member

Oleg Nodelman

Board member

Oleg Nodelman is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, which invests in companies at all stages of research and development. With over twenty years of experience in biotech investing, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities.

Before founding EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners, one of the first hedge funds dedicated to investing in the biotechnology sector. He currently serves as a Board Member for three publicly traded companies: AnaptysBio (NASDAQ: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics applicable to inflammatory and autoimmune diseases, Galapagos (Euronext & NASDAQ: GLPG), a clinical-stage biotechnology company focused on small molecules, CAR-T therapies, and biologics in oncology and immunology, and Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease.

Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.

Dimitri Papalexopoulos

Board member

Dimitri Papalexopoulos

Board member

Dimitri is Chairman of Titan Cement Group, a cement and building materials producer active since 1902. The group directly employs about 5,500 people, operates cement plants in 10 countries, and is active in many more. Prior to joining Titan in 1989, Dimitri started his career as a business consultant for McKinsey & Company in the USA and Germany.

He is a member of the European Round Table for Industry (ERT) and chairs the ERT’s Energy Transition & Climate Change Committee. He sits on the boards of the Foundation for Economic and Industrial Research (IOBE), the Hellenic Foundation for European and Foreign Policy (ELIAMEP), and Endeavor Greece. He has previously served as Chairman of the Board of the Hellenic Federation of Enterprises (SEV).

Dimitri holds a M.Sc. in Electrical Engineering from the Swiss Federal Institute of Technology (ETHZ) and an MBA from Harvard Business School.

Brad Prosek

Board member

Brad Prosek

Board member

Brad has been in the biotechnology / life sciences business for over 25 years. He is currently the President and CEO of Calytrix Bio. Most recently, he was an Operating Partner at EcoR1 Capital, a biotech-focused investment advisory firm. Prior to that he served as SVP and Chief Business Officer at Constellation Pharmaceuticals, an oncology-focused biotech company, from September 2017 until the company was acquired by MorphoSys AG in July 2021. During his tenure, Brad led Corporate Development and Strategy efforts, including Business Development, Commercial Strategy, and Program Leadership. He contributed to multiple financings and overall company operational oversight as a member of Constellation’s executive team.

Prior to joining Constellation, Brad founded and served as President of All Terrain bioPartners LLC, a business development consulting firm. While running All Terrain bioPartners, he advised and provided interim general management services to a global set of life sciences companies. Before that, Brad spent 10 years building Cubist Pharmaceuticals, Inc., a leading biopharmaceutical company in the hospital anti-infectives and products space, from early in its commercialization of its flagship product CUBICIN (daptomycin) through the company’s acquisition by Merck. Prior to Cubist, Brad worked in the US and Europe in commercial operations and business development roles at Biogen and helped to build one of the earliest market access consulting firms to support life sciences companies. He has also served as an advisor to Xenex Disinfection, a medical device company, as well as international relations education-focused nonprofits.

Brad holds an MBA from Columbia University and a BS in Foreign Service from Georgetown University, with a concentration in Science & Technology in International Relations.

Amit Singhal, PhD

Advisor

Amit Singhal, PhD

Advisor

Amit is known as the man behind Google Search, having led the Google Search team for over 15 years - from its early days in 2000 until his departure in 2016. He has received several awards and distinctions, including being named a Google Fellow, elected to the National Academy of Engineering, elected Fellow of the ACM (Association for Computing Machinery), and called one of the "smartest people in tech" by Fortune magazine.

He is currently dedicated to giving back to his community through the Sitare Foundation (www.sitare.org), a non-profit organization that he co-founded together with his wife, Shilpa. Sitare is focusing on providing access to high quality education to the most talented underprivileged children in India. Amit is also an active angel investor and an advisor to technology companies globally.

He holds a Bachelor of Engineering degree from IIT Roorkee, an MS from the University of Minnesota Duluth, and a PhD from Cornell University, all in Computer Science and Information Retrieval.

Anastasia Tzortzi

VP, People & Culture

Anastasia Tzortzi

VP, People & Culture

Anastasia leads our people strategy, shaping how we build exceptional teams and how we support, develop, and grow our people and culture across different geographies.

With over a decade of experience in building high-performing teams across multiple industries, she has held key roles including Recruitment Coordinator at Amazon in Prague, Talent Advisor at Microsoft, HR Project Specialist at the European Union Agency for Cybersecurity (ENISA), and HR Manager at Glami, an e-commerce fashion aggregator. Her career journey began at Disneyland Paris, where she first discovered her passion for people and culture.

Anastasia holds a BA in European Studies & International Relations from Panteion University of Social and Political Sciences in Athens, as well as a double MSc in International Marketing from IPAG Business School (Paris) and Napier University (Edinburgh).

Alex Tzoukas

Board member

Alex Tzoukas

Board member

Alex has 15+ years of experience in life sciences investing and investment banking. He is currently Managing Partner and co-founder at Kos Biotechnology Partners, a venture capital firm dedicated to life sciences.

Previously he was Principal at Gurnet Point Capital, a Boston-based life sciences VC / PE fund, and an investment banker with Deutsche Bank and MTS Health Partners in New York. Prior to that he was an investor at Global Finance and Alpha Bank in Greece. He holds an MBA from Harvard Business School.

Nassos Zarkalis

Advisor

Nassos Zarkalis

Advisor

Nassos brings 30 years of experience in building and running customer-facing organizations, with a passion for delighted customers, operational excellence, and smart capital allocation. He currently serves as the chairman of Ethniki Insurance, and as a member of the board of the National Bank of Greece.

Until recently, and for more than ten years, Nassos served as Chairman and CEO of Wind Hellas, a leading telecoms player in Greece. Working with US-based private equity partners, he led a radical business transformation that resulted in remarkable value creation upon the company's acquisition by BC Partners-owned United Group in 2022. Repositioning the company on a platform of low-cost but high-performing customer acquisition and retention was core to this journey.

Prior to Wind, Nassos was CEO of Hellas on Line (HoL), a Greek fixed line telecoms player; again a case of rapid business turnaround on the basis of operational excellence and smart investing. He has also held various commercial roles with Vodafone in Greece and abroad. Before his career in telecommunications, he worked for leading FMCG companies, including P&G and PepsiCo, in sales and marketing roles.

Nassos holds a BS in Chemical Engineering from the National Technical University of Athens (NTUA), an MS in Chemical Engineering from the University of Delaware, and an MBA from Henley Business School.

Our locations

New York

 

View on map

Athens

 

View on map
Our locations

Collaboration

Got a project?
Let's talk.

Contact Us

We combine specialized life sciences expertise with cost-effective talent and cutting-edge AI solutions, helping your team communicate more effectively, strengthen connections with healthcare professionals and patients, and ultimately drive measurable impact across every touchpoint.